LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Omnicell Inc

Fechado

SetorSaúde

34.89 1.87

Visão Geral

Variação de preço das ações

24h

Atual

Mín

34.26

Máximo

35.44

Indicadores-chave

By Trading Economics

Rendimento

-7.5M

-2M

Vendas

3.4M

314M

P/E

Médio do Setor

857.25

57.833

EPS

0.51

Margem de lucro

-0.645

Funcionários

3,580

EBITDA

-9.8M

21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+69.73% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-679M

1.6B

Abertura anterior

33.02

Fecho anterior

34.89

Sentimento de Notícias

By Acuity

50%

50%

156 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Omnicell Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mar. de 2026, 22:42 UTC

Ganhos

Prudential PLC 2025 Adjusted Operating Profit Rises

17 de mar. de 2026, 21:40 UTC

Ganhos

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 de mar. de 2026, 23:56 UTC

Conversa de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 de mar. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de mar. de 2026, 23:42 UTC

Conversa de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 de mar. de 2026, 23:38 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

17 de mar. de 2026, 23:24 UTC

Conversa de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 de mar. de 2026, 22:22 UTC

Conversa de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 de mar. de 2026, 22:20 UTC

Ganhos

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 de mar. de 2026, 22:07 UTC

Ganhos

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 de mar. de 2026, 22:05 UTC

Ganhos

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 de mar. de 2026, 22:04 UTC

Ganhos

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 de mar. de 2026, 22:03 UTC

Ganhos

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 de mar. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 de mar. de 2026, 21:26 UTC

Ganhos

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 de mar. de 2026, 21:09 UTC

Ganhos

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 de mar. de 2026, 21:08 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:07 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:06 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Rev $21.8B >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q EPS 82c >ATD.T

17 de mar. de 2026, 21:05 UTC

Ganhos

Couche-Tard 3Q Net $757.2M >ATD.T

17 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Energy & Utilities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Omnicell Inc Previsão

Preço-alvo

By TipRanks

69.73% parte superior

Previsão para 12 meses

Média 58.2 USD  69.73%

Máximo 70 USD

Mínimo 49 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Omnicell Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

6

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

24.23 / 30.44Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

156 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat